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median follow up of 18 (6-54) months. Eighteen pts have died; 9
from non-relapse causes (8/9 died of infections  GVHD) and 9
from relapse/PD a median of 7 (range 1-38) months post trans-
plant. Day 100 and 1 year NRM was 7% and 35% respectively.
One year overall survival, progression free survival and relapse/PD
incidence were 51%, 18% and 47% respectively. A detailed de-
scription of the MRD and URD pts is shown in Table 1. In
summary, salvage nonmyeloablative conditioning and allogeneic
HCT provides anti-tumor activity in pts with relapsed or refrac-
tory HD who are ineligible for conventional allogeneic transplant.
Future efforts incorporating tumor-speciﬁc antibody therapy after
nonmyeloablative conditioning HCT are being developed in an
effort to improve disease free survival, anti-tumor activity and
overall survival in pts with relapsed or refractory HD.
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RISK-FACTORS OF MELPHALAN/FLUDARABINE DOSE-REDUCED ALLO-
GENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE
MYELOMA
Kroger, N.1, Perez-Simon, J.A.2, Myint, H.3, Klingemann, H.3, Shi-
moni, A.4, Nagler, A.4, Martino, R.5, Allegre, A.6, Tomas, J.7, Schw-
erdtfeger, R.8, Kiehl, M.9, Fauser, A.9, Sayer, H.G.10, Leon, A.11,
Beyer, J.12, Zabelina, T.1, Ayuk, F.1, San Miguel, J.2, Brand, R.13,
Zander, A.1 1. Bone Marrow Transplantation-University Hamburg,
Hamburg, Germany; 2. Hospital Clinico Universitario, Salamanca,
Spain; 3. Dept of BMT, Rush-University Medical Center, Chicago, IL;
4. Bone Marrow Transplantation, Tel Hashomer, Israel; 5. Hosital de la
Santa Creu I Sant Pau, Barcelona, Spain; 6. Hospital de la Princesa,
Madrid, Spain; 7. Fundacion Jimenez Diaz, Madrid, Spain; 8. Bone
Marrow Transplantation, Wiesbaden, Germany; 9. Bone Marrow
Transplantation, Idar-Oberstein, Germany; 10. Dept of Oncology and
Hematology, Jena, Germany; 11. Hospital de la Seguridad Social, Jerez,
Spain; 12. Dept of Hematology and Oncology, Marburg, Germany; 13.
Dept of Medical Statistics, Leiden, Netherlands
To evaluate the impact of timing of dose-reduced allograft in
patients with multiple myeloma, we analyzed 120 patients in a
retrospective study, who were treated with melphalan/ﬂudarabine
as conditioning regimen. The cumulative risk at one year for
treatment-related mortality (TRM) was 18% (95% CI: 12-28%).
In a multivariate analysis, relapse after prior high-dose chemother-
apy was the most signiﬁcant factor for TRM (HR 2.80; 95% CI:
1.16-6.74; p  0.02), relapse (HR 4.14; 95% CI: 2.04-8.38, p 
0.001), event-free (HR 3.11; 95% CI: 1.77-5.46; p  0.001), and
overall survival (HR 2.69; 95% CI: 1.35-5.35; p  0.005). In
addition, relapse was also signiﬁcantly diminished by chronic
GvHD in a time-dependent Cox model (HR 0.37; 95% CI: 0.16-
0.87; p  0.02), while trans-plantation with peripheral blood stem
cells (PBSC) resulted in better overall survival (HR 0.35; 95% CI:
0.14-0.88; p  0.002). In a subgroup of patients with chemosen-
sitivity at time of transplantation and no relapse after a prior
high-dose chemotherapy who were transplanted with PBSC (n 
46), the cumulative risk of TRM at one year was only 8% (95% CI:
1-54%), and the two-year estimated event-free and overall survival
was 60% (95% CI: 42-78%) and 75% (95% CI: 59-91%) for
related (n  34), and 81% (95% CI: 59-100%) and 92% (95% CI:
76-100%) for unrelated donors (n  12). We conclude that dose-
reduced allograft with related and unrelated donors should be
performed at an earlier stage of the disease in patients who are
chemosensitive and without relapse after a prior autograft, result-
ing in a lower TRM and better event-free and overall survival.
PEDIATRIC DISORDERS
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TRANSPLANTATION OF BOYS WITH X-LINKED ADRENOLEUKODYS-
TROPHY WITH UNRELATED-DONOR, PARTIALLY HLA-MISMATCHED
BANKED UMBILICAL CORD BLOOD
Allison, J., Martin, P.L., Szabolcs, P., Driscoll, T., Parikh, S., Wood, S.,
Kurtzberg, J. Duke University Medical Center, Durham, NC
Introduction: X-linked adrenoleukodystrophy causes dysmyeli-
nation and fatal neurodegenerative disease in 30%-50% of affected
patients. Bone marrow transplantation has been shown to prevent
progression of neurologic disease if performed early in the course
of the disease. As some children lack suitably matched bone mar-
row donors, we explored the efﬁcacy of using partially mismatched
unrelated donor umbilical cord blood transplantation to treat this
disease. Methods: Between 11/1996 and 7/03, 10 boys with a
median age of 7 years (range 2-26 years) were prepared for trans-
plantation with busulfan, cyclophosphamide, and ATG and trans-
planted with 4/6 HLA-matched (n  6) or 5/6 (n  4) unrelated
umbilical cord blood. The median cell dose administered by the
graft was 6.84  10e7cells/kg (range 2.83-14.19) and median
CD34 dose was 2.42  10e5/kg (range 0.48-5.46). GvHD prophy-
laxis was given with cyclosporine and steroids. All boys received
stress dose steroids as coverage for adrenal insufﬁciency. Support-
ive care consisted of IVIG, empiric antifungals and antivirals, TPN
without intralipids, and G-CSF. Results: All boys engrafted with
donor neutrophils in a median of 22 days (range 13-48) days.
Platelets reached 50K/uL without transfusion support in a median
of 75 days (range 25-227 days). Two patients (20%) had grade
II-IV acute GvHD (both grade IV) and recovered. All patients are
surviving with durable grafts with median EFS of 330 days (range
94-2523 days). All patients had progressive changes on MRI at the
time of transplant. Those transplanted before the onset of signif-
icant clinical symptoms have all done well (n  6) and have not
experienced progression of neurologic disease. These patients have
also demonstrated normalization of nerve conduction studies post
transplant. Four patient had progressive clinical symptoms in the 2
months before transplant. Three of the four progressed post trans-
plant before stabilizing at a lower level of functioning. One patient,
the oldest at transplant, had progressive visual losses but improve-
ment in neuromotor function and peripheral neuropathy. Conclu-
sions: We conclude that unrelated donor, partially mismatched
cord blood is a viable and readily available alternative donor for
patients with X-linked ALD requiring transplantation therapy.
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DIMINISHED SICKLE CELL ADHESION MOLECULES FOLLOWING BONE
MARROW TRANSPLANTATION (BMT)
Baothman, A.A.1, Kuvibidila, S.R.2, Yu, L.C.2 1. King Faisal Specialist
Hospital & RC, Riyadh, Centeral Province, Saudi Arabia; 2. Louisiana
State University, NewOrleans, LA
To determine whether stem cell allograft affects the expression
and interaction of adhesion molecules on both sickle red cell and
endothelial cells, we examined baseline and follow-up of vascular
Table. Results of Nonmyeloablative Conditioning Followed by
Allogeneic HCT for HD Using MRD or URD
MRD
(n  18)
URD
(n  9)
Median follow up of living
patients (range)
36 (12-54)
months
11 (6-24)
months
Disease status at HCT 4 CR, 7 PR,
4 Rel, 3 Ref
1 CR, 4 PR,
4 Ref
Overall response rate 57% (7 CR,
1 PR)
50% (3 CR,
1 PR)
Living patients/status 3 CR, 2 PD 3 CR, 1 Rel
Acute GVHD grade II, III, IV 33%, 11%, 6% 33%, 22%, 0%
1 year chronic extensive
GVHD
50% 60%
Day 100 NRM 11% 0%
One year NRM 39% 26%
One year overall survival 39% 75%
One year progression free
survival
11% 35%
One year Rel/PD incidence 50% 40%
Rel, relapse; Ref, refractory.
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cell adhesion molecule-1 (VCAM-1), alpha-1 acid glycoprotein
(AGP) and C-reactive Protein (CPR) for two homozygous sickle
cell patients, and it’s association with clinical episodes, hemoglobin
S% determination and donor cell percentages. We report two
patients with Sickle cell disease (SCD) had multiple Cerebro-
Vascular-Accident (CVA) and recurrent vasco-occulsive crises and
failed to respond to chronic transfusion program with Desferal
rescue, underwent HLA-matched Allogenic Bone Marrow Trans-
plantation (BMT). Patients were prepared for transplantation us-
ing standard regimen which comprised Busulfan (BU) 3.5 mg/kg
PO every 6H for total of 16 doses, four days of Cytoxan (50 mg/kg)
and, ATG (30mg/kg) for 3days. Both were given antiseizure pro-
phylaxis from day-2 to day 14 and continued with cyclosporin
(1.5 mg/kg) for 6 months post-transplant and because of poor renal
function patient #1 received methylprednisone 1mg/kg as alterna-
tive to methetotrexate while patient #2 received standard short
course of methetrexate for GVHD prophylaxis. Neutrophil En-
graftment (0.5 109/L) occurred in day10, day14 respectively
with augmentation of GCSF. Both had stable clinical and cytogen-
tic engraftment. Post BMT complication were signiﬁcant for SVS
(superior vena cava syndrome) which completely resolved with r
TPA for patient #1 and chronic cutenous GVHD for patient #2
which managed with steroid. Pre BMT adhesion molecules
VCAM-1, AGP and plasma factor CRP were determined and
correlated with clinical episodes of crises, Hgb S% and donor cell
percentage. VCAM-1 level was 1041 ng/ml, AGP 1.14 mg/L, and
CRP 11.64 mg/L on day –4 for patient #1 which declined by 38%
on day 16 for VCAM-1 16%, and 100% for AGP and CRP
respectively. While VCAM-1 level was 3404 ng/ml, AGP 1.14
mg/L, and CRP 11.64 mg/L for patient #2 on day-2, these were
noticed to decline gradually and reach minimum of 970 ng/ml
(down by 71%) of VCAM-1, 1.0 mg/L of AGP (12%), and almost
100% decrease of CRP. Our results suggest the role of Stem cell
allograft in reversing the progression of vasculopathy through
decreasing adherence and interaction of both red cell, endothelial
cell and plasma factors.
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THE USE OF FLUDARABINE BASED REDUCED INTENSITY CONDITION-
ING FOR THE TREATMENT OF PATIENTS WITH FANCONI’S ANEMIA
Slavin, S., Bitan, M., Aker, M., Resnik, I., Shapira, M.Y., Or, R.
Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Allogeneic stem cell transplantation (SCT) is the only curative
modality for Fanconi’s anemia (FA). FA patients are most susceptible
to alkylating agents and radiation at dose ranges commonly used in
preparation for SCT. For FA, ﬂudarabine based non-myeloablative
stem cell transplantation (NST) is particularly attractive for reducing
toxicity and improving immediate and long-term outcome following
SCT. Sixteen FA patients were transplanted in our center between
1989-2002. Eight patients were transplanted with cyclophosphamide
and ionizing irradiation (total lymphoid irradiation) (CY-TLI). Six
patients were treated, with NST consisting of ﬂudarabine 30mg/
meter sq/day  6; cyclophosphamide 5mg/kg/day 2 and rabbit
anti-T lymphocyte globulin (ATG) 10mg/kg 4. Higher dose of
cyclophosphamide of 10mg/kg/day 2 was used in a patient with
leukemic transformation with thrombocytopenia and 20% myelo-
blasts. The regimen was well tolerated with no transplant related
toxicity or any major complication. However, rejection was observed
when the protocol was applied for a matched unrelated donor
(MUD). A second transplant from another unrelated donor was suc-
cessfully accomplished without complications using a combination of
ﬂudarabine, busulfan 4mg/kg/day 2 and Campath-1H (humanized
anti-CD52), and therefore, it was decided that this protocol will also
be used for a subsequent case. All 8/8 patients treated with NST with
stem cells obtained from a matched sibling or MUD survive, follow-
ing uneventful SCT procedure with 100% donor cell chimerism, fully
reconstituted with no severe acute or chronic GVHD, whereas in the
CY-TLI group 50% are currently alive post transplantation. More-
over, looking at several parameters associated with post-transplant
complications, like fever, infections, the need for total parental nutri-
tion, veno-occlusive disease of the liver and graft-versus-host disease,
NST protocol appears superior according to all parameters. Based on
our data, ﬂudarabine based NST may represent the treatment of
choice for patients with FA with a matched sibling or MUD available.
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REDUCED INTENSITY (RI) CONDITIONING AND ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) IN PEDIATRIC PA-
TIENTS WITH NON-MALIGNANT DISORDERS
Jacobsohn, D.A., Kletzel, M., Duerst, R. Children’s Memorial Hospital,
Chicago, IL
Because children tolerate intensive regimens with less TRM,
there has been reluctance to use RI regimens in them despite
potential beneﬁt for reduced long-term morbidity. RI regimens are
of interest in children with nonmalignant disorders since there’s no
obvious need for high-dose therapy or GVL. Of 30 pts who
underwent RI HSCT at Children’s Memorial Hospital, 12 (6M,
6F) had nonmalignant disorders. Diagnoses: 5 immunodeﬁciencies
(2 Hyper-IgM, 1 Omenn’s, 1 X-linked lymphoproliferative dis-
ease, 1 chronic granulomatous disease), 3 metabolic disorders (1
Hurler’s, 1 mucolipidosis II/III, 1 Sandhoff), 4 hemoglobinopa-
thies (3 sickle cell, 1 beta-thalassemia). Median age: 6 yrs (range
0.5-22.5). Stem cell sources: PBSC from 6 unrelated donors, 4
matched siblings, 1 mismatched parent, and 1 unrelated cord
blood. Regimen: ﬂudarabine 30 mg/m2 (day (d) –10 to –5), IV
busulfan, 0.8-1 mg/kg8 doses or 3.2 mg/kg 2 doses (d –5 and
–4), and equine ATG 40 mg/kg or rabbit ATG 2 mg/kg (d –4 to
–1). GVHD prophylaxis: CsA (7), CsA/MMF (5). Median time to
ANC 500/ul  19 d (10-61), and to unsupported platelet
count  20,000/ul  16.5 d (10-61). Median time to full donor
chimerism (VNTR 95-100%)  143 d (14-473) in 8 of 11 evalu-
able pts (1 hyper-IgM pt remains a mixed chimera, 2 with hemo-
globinopathies never developed donor chimerism). One hemoglo-
binopathy pt achieved full donor chimerism but rejected at 2 yrs
(after PBSC boost). Post-HSCT PBSC boosts were given to 5 pts
for falling donor chimerism. One pt developed aGVHD II-IV; 3 of
8 surviving past d100 with donor chimerism developed limited (2)
or extensive (1) cGVHD. Median survival is 609 d (7-1251). Of 12
pts, 8 are alive. 100d TRM occurred in 2 (measles encephalitis in
1, ARDS in Omenn’s pt who began conditioning with active
infection/ARDS and died d7). Six of the survivors continue to
show donor chimerism. The 2 survivors with autologous recovery
are hemoglobinopathy pts. Whereas 1 of 4 hemoglobinopathy pts
had sustained engraftment, 7 of the 7 remaining evaluable pts have
stable engraftment. Immunodeﬁciency pts had obvious clinical
beneﬁt from HSCT but more time is needed to assess impact of RI
HSCT in pts with metabolic disorders. In children with nonma-
lignant disorders other than hemoglobinopathies, this RI regimen
is relatively non-toxic and promotes engraftment, even with unre-
lated donors. However, in children with hemoglobinopathies, this
RI regimen is associated with non-engraftment or late graft rejec-
tion and should not be performed.
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A TEST DOSE OF I.V. BUSULFAN (BU) IS PREDICTIVE OF THE AREA
UNDER THE CURVE (AUC) OF A SINGLE DAILY DOSE OF I.V. BU IN
PEDIATRIC PATIENTS UNDERGOING A REDUCED INTENSITY (RI) HE-
MATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Kletzel, M., Jacobsohn, D., Duerst, R. Northwestern University Child-
rens Memorial Hospital, Chicago, IL
High-dose BU-containing chemotherapy has been used in autol-
ogous and allogeneic HSCT. Variations in the PK for oral BU in
pediatric patients have resulted in either decreased effect or in-
creased toxicity. The IV formulation eliminates the variability of
Table.
VCAM
ng/mL
(#1)
AGP
mg/L
(#1)
CRP
mg/L
(#1)
VCAM
ng/mL
(#2)
AGP
mg/L
(#2)
CRP
mg/L
(#2)
Post BMT 871 0.948 0 970 1.0 0
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